Anti-integrin αvβ6 antibody in Takayasu arteritis patients with or without ulcerative colitis

It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1387516
Main Authors Ishikawa, Yuki, Yoshida, Hiroyuki, Yoshifuji, Hajime, Ohmura, Koichiro, Origuchi, Tomoki, Ishii, Tomonori, Mimori, Tsuneyo, Morinobu, Akio, Shiokawa, Masahiro, Terao, Chikashi
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 09.05.2024
Subjects
Adult
Alleles
anti-integrin αvβ6 antibody
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Autoantibodies - blood
Autoantibodies - immunology
Colitis, Ulcerative - genetics
Colitis, Ulcerative - immunology
Female
Genotype
HLA-B52
HLA-B52 Antigen - genetics
HLA-B52 Antigen - immunology
Humans
Immunology
Integrins - immunology
Japan - epidemiology
Male
Middle Aged
Takayasu Arteritis - genetics
Takayasu Arteritis - immunology
Takayasu’s arteritis
ulcerative colitis
vasculitis
Young Adult
Japan
ulcerative colitis
Takayasu’s arteritis
anti-integrin αvβ6 antibody
HLA-B52
vasculitis
Online AccessGet full text

Cover

Abstract It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles. A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation. The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10 ). A total of 99 out of 218 (45.4%) patients were carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189). The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of on anti-integrin αvβ6 Ab production would be minimal.
AbstractList BackgroundIt has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles.MethodsA total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.ResultsThe information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10-8). A total of 99 out of 218 (45.4%) patients were HLA-B*52 carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and HLA-B*52 carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189).ConclusionsThe prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of HLA-B*52 on anti-integrin αvβ6 Ab production would be minimal.
It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles. A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation. The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10 ). A total of 99 out of 218 (45.4%) patients were carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189). The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of on anti-integrin αvβ6 Ab production would be minimal.
It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles.BackgroundIt has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the co-occurrence, which is one of the common genetic features between these two diseases, indicating shared underlying pathologic mechanisms. Anti-integrin αvβ6 antibody (Ab) is present in sera of UC patients in a highly specific manner. We investigated if there were any associations between anti-integrin αvβ6 Ab and TAK, considering the risk HLA alleles.A total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.MethodsA total of 227 Japanese TAK patients were recruited in the current study and their serum samples were subjected to measurement of anti-integrin αvβ6 Ab by ELISA. The clinical information, including the co-occurrence of UC, was collected. The HLA allele carrier status was determined by Luminex or genotype imputation.The information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10-8). A total of 99 out of 218 (45.4%) patients were HLA-B*52 carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and HLA-B*52 carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189).ResultsThe information about the presence of UC was available for 165 patients, among which eight (4.84%) patients had UC. Anti-integrin αvβ6 antibody was identified in 7 out of 8 TAK subjects with UC (87.5%) while only 5 out of 157 (3.18%) TAK subjects without UC had the antibody (OR 121, p=7.46×10-8). A total of 99 out of 218 (45.4%) patients were HLA-B*52 carriers. There was no significant association between the presence of anti-integrin αvβ6 Ab and HLA-B*52 carrier status in those without UC (OR 2.01, 95% CI 0.33-12.4, p = 0.189).The prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of HLA-B*52 on anti-integrin αvβ6 Ab production would be minimal.ConclusionsThe prevalence of anti-integrin αvβ6 Ab was high in TAK patients with UC, but not in the absence of concomitant UC. The effect of HLA-B*52 on anti-integrin αvβ6 Ab production would be minimal.
Author Ishikawa, Yuki
Ohmura, Koichiro
Yoshida, Hiroyuki
Mimori, Tsuneyo
Terao, Chikashi
Ishii, Tomonori
Shiokawa, Masahiro
Origuchi, Tomoki
Morinobu, Akio
Yoshifuji, Hajime
AuthorAffiliation 7 Clinical Research, Innovation and Education Center, Tohoku University Hospital , Sendai , Japan
9 Clinical Research Center, Shizuoka General Hospital , Shizuoka , Japan
6 Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan
8 Department of Rheumatology, Ijinkai Takeada General Hospital , Kyoto , Japan
2 Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine , Kyoto , Japan
10 The Department of Applied Genetics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka , Japan
4 Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto , Japan
1 Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN , Yokohama , Japan
5 Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe , Japan
3 Department of Gastroenterology, Kans
AuthorAffiliation_xml – name: 3 Department of Gastroenterology, Kansai Electric Power Hospital , Osaka , Japan
– name: 8 Department of Rheumatology, Ijinkai Takeada General Hospital , Kyoto , Japan
– name: 10 The Department of Applied Genetics, School of Pharmaceutical Sciences, University of Shizuoka , Shizuoka , Japan
– name: 4 Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University , Kyoto , Japan
– name: 9 Clinical Research Center, Shizuoka General Hospital , Shizuoka , Japan
– name: 6 Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan
– name: 7 Clinical Research, Innovation and Education Center, Tohoku University Hospital , Sendai , Japan
– name: 5 Department of Rheumatology, Kobe City Medical Center General Hospital , Kobe , Japan
– name: 1 Laboratory for Statistical and Translational Genetics, Center for Integrative Medical Sciences, RIKEN , Yokohama , Japan
– name: 2 Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine , Kyoto , Japan
Author_xml – sequence: 1
  givenname: Yuki
  surname: Ishikawa
  fullname: Ishikawa, Yuki
– sequence: 2
  givenname: Hiroyuki
  surname: Yoshida
  fullname: Yoshida, Hiroyuki
– sequence: 3
  givenname: Hajime
  surname: Yoshifuji
  fullname: Yoshifuji, Hajime
– sequence: 4
  givenname: Koichiro
  surname: Ohmura
  fullname: Ohmura, Koichiro
– sequence: 5
  givenname: Tomoki
  surname: Origuchi
  fullname: Origuchi, Tomoki
– sequence: 6
  givenname: Tomonori
  surname: Ishii
  fullname: Ishii, Tomonori
– sequence: 7
  givenname: Tsuneyo
  surname: Mimori
  fullname: Mimori, Tsuneyo
– sequence: 8
  givenname: Akio
  surname: Morinobu
  fullname: Morinobu, Akio
– sequence: 9
  givenname: Masahiro
  surname: Shiokawa
  fullname: Shiokawa, Masahiro
– sequence: 10
  givenname: Chikashi
  surname: Terao
  fullname: Terao, Chikashi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38784377$$D View this record in MEDLINE/PubMed
BookMark eNpVUktuFDEUtFAQCSEXYIF6yaYH_-1eoSjiEykSm7C23P5MHLrbg-2eaI4FB8mZcM8MUVKbZ9Ur17P16i04meLkAHiP4IoQ2X3yYRznFYaYrhCRgiH-CpwhzmlLMKYnz86n4CLne1hBO0IIewNO6wVJiRBnQF1OJbRhKm6dwtQ8_tk-_uWNrmQf7a6p1K3-pXc6z41OxaVQQm42ugQ3ldw8hHLXxLSvcS7NPBiXanPrGhOHRfsOvPZ6yO7iWM_Bz69fbq--tzc_vl1fXd60hmJYWqmNFBYhK3tjOZWUUWysoz0jnlrhOuyNINIj0WHkO6MZ5w4z7TXRTEpMzsH1wddGfa82KYw67VTUQe2JmNaqvj-YwSnDoO0x6g1ihNrOae8g5pIggSsErF6fD16buR-dNfWrSQ8vTF92pnCn1nGr0ALJSHX4eHRI8ffsclFjyMYNg55cnLMikEMil41U6Yfnw56m_F9RFeCDwKSYc3L-SYKgWqKg9lFQSxTUMQrkHyOSqng
Cites_doi 10.1016/j.cgh.2021.12.035
10.1073/pnas.1808850115
10.31662/jmaj.2023-0038
10.1002/art.39157
10.1097/BOR.0000000000000852
10.1136/ard-2022-223482
10.1016/s0167-5273(96)88774-2
10.1002/art.1780330811
10.3109/03009742.2015.1060521
10.1038/s41467-020-15088-0
10.1016/j.ajhg.2013.05.024
10.1038/ng.764
10.1093/ecco-jcc/jjy113
10.1053/j.gastro.2011.05.048
10.1172/JCI31027
10.1111/j.1399-0039.1993.tb02172.x
10.1097/MEG.0000000000001490
10.1253/circj.CJ-19-0773
10.1053/j.gastro.2021.02.019
10.1007/s00535-014-1016-1
10.1093/rheumatology/ket241
10.1007/s00535-021-01784-1
10.1111/1756-185X.12309
10.1016/j.ajhg.2013.05.026
10.1016/j.ajhg.2020.11.014
ContentType Journal Article
Copyright Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao.
Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao
Copyright_xml – notice: Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao.
– notice: Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2024.1387516
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_c50db21bc1534d9eafe0268317222270
PMC11111853
38784377
10_3389_fimmu_2024_1387516
Genre Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
CGR
CUY
CVF
ECM
EIF
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c420t-8ac87d11d8bcd6484542cde4b53f4d7e92fc738f17921f9ca566e25afa3a58823
IEDL.DBID M48
ISSN 1664-3224
IngestDate Wed Aug 27 01:29:05 EDT 2025
Thu Aug 21 18:35:05 EDT 2025
Fri Jul 11 16:40:48 EDT 2025
Thu Apr 03 07:01:30 EDT 2025
Tue Jul 01 01:40:39 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords ulcerative colitis
Takayasu’s arteritis
anti-integrin αvβ6 antibody
HLA-B52
vasculitis
Language English
License Copyright © 2024 Ishikawa, Yoshida, Yoshifuji, Ohmura, Origuchi, Ishii, Mimori, Morinobu, Shiokawa and Terao.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-8ac87d11d8bcd6484542cde4b53f4d7e92fc738f17921f9ca566e25afa3a58823
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Emanuele Bizzi, ASST Fatebenefratelli Sacco, Italy
Jayakanthan Kabeerdoss, Post Graduate Institute of Medical Education and Research (PGIMER), India
Edited by: Joshua Daniel Ooi, Monash University, Australia
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fimmu.2024.1387516
PMID 38784377
PQID 3060380004
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_c50db21bc1534d9eafe0268317222270
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11111853
proquest_miscellaneous_3060380004
pubmed_primary_38784377
crossref_primary_10_3389_fimmu_2024_1387516
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-05-09
PublicationDateYYYYMMDD 2024-05-09
PublicationDate_xml – month: 05
  year: 2024
  text: 2024-05-09
  day: 09
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2024
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Terao (B6) 2016; 45
Saruhan-Direskeneli (B5) 2013; 93
Kourkoulis (B7) 2019; 31
Arend (B10) 1990; 33
Kakuta (B22) 2023; 21
Yoshida (B3) 1993; 42
Terao (B4) 2013; 93
Anderson (B16) 2011; 43
Isobe (B12) 2020; 84
Nakase (B14) 2021; 56
Esatoglu (B2) 2022; 34
Terao (B1) 2014; 17
Yoshida (B15) 2015; 50
Kuwada (B8) 2021; 160
Mutoh (B21) 2020; 11
Okada (B17) 2011; 141
Terao (B18) 2013; 52
Scaldaferri (B23) 2007; 117
Terao (B9) 2015; 67
Kimura (B19) 1996
Ortiz-Fernández (B25) 2021; 108
Maaser (B13) 2019; 13
Grayson (B11) 2022; 81
Terao (B24) 2018; 115
Shirai (B20) 2023; 6
References_xml – volume: 21
  year: 2023
  ident: B22
  article-title: Novel diagnostic autoantibodies against endothelial protein C receptor in patients with ulcerative colitis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2021.12.035
– volume: 115
  year: 2018
  ident: B24
  article-title: Genetic determinants and an epistasis of
  publication-title: Proc Natl Acad Sci USA
  doi: 10.1073/pnas.1808850115
– volume: 6
  year: 2023
  ident: B20
  article-title: Common autoantibody among takayasu arteritis and ulcerative colitis: A possible pathophysiology that includes gut-vessel connection in vascular inflammation
  publication-title: JMA J
  doi: 10.31662/jmaj.2023-0038
– volume: 67
  year: 2015
  ident: B9
  article-title: Takayasu arteritis and ulcerative colitis: high rate of co-occurrence and genetic overlap
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.39157
– volume: 34
  start-page: 18
  year: 2022
  ident: B2
  article-title: Takayasu arteritis
  publication-title: Curr Opin Rheumatol
  doi: 10.1097/BOR.0000000000000852
– volume: 81
  year: 2022
  ident: B11
  article-title: 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard-2022-223482
– year: 1996
  ident: B19
  article-title: Comprehensive analysis of HLA genes in Takayasu arteritis in Japan
  publication-title: Int J Cardiol
  doi: 10.1016/s0167-5273(96)88774-2
– volume: 33
  year: 1990
  ident: B10
  article-title: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis
  publication-title: Arthritis Rheumatol
  doi: 10.1002/art.1780330811
– volume: 45
  year: 2016
  ident: B6
  article-title: Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application
  publication-title: Scand J Rheumatol
  doi: 10.3109/03009742.2015.1060521
– volume: 11
  start-page: 1253
  year: 2020
  ident: B21
  article-title: Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-15088-0
– volume: 93
  year: 2013
  ident: B4
  article-title: Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2013.05.024
– volume: 43
  year: 2011
  ident: B16
  article-title: Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
  publication-title: Nat Genet
  doi: 10.1038/ng.764
– volume: 13
  year: 2019
  ident: B13
  article-title: ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications
  publication-title: J Crohns Colitis
  doi: 10.1093/ecco-jcc/jjy113
– volume: 141
  start-page: 864
  year: 2011
  ident: B17
  article-title: HLA-Cw*1202-B*5201-DRB1*1502 haplotype increases risk for ulcerative colitis but reduces risk for Crohn's disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.05.048
– volume: 117
  year: 2007
  ident: B23
  article-title: Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease
  publication-title: J Clin Invest
  doi: 10.1172/JCI31027
– volume: 42
  start-page: 87
  year: 1993
  ident: B3
  article-title: DNA typing of HLA-B gene in Takayasu's arteritis
  publication-title: Tissue Antigens
  doi: 10.1111/j.1399-0039.1993.tb02172.x
– volume: 31
  year: 2019
  ident: B7
  article-title: Novel potential biomarkers for the diagnosis and monitoring of patients with ulcerative colitis
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/MEG.0000000000001490
– volume: 84
  start-page: 299
  year: 2020
  ident: B12
  article-title: JCS 2017 guideline on management of vasculitis syndrome- digest version
  publication-title: Circ J
  doi: 10.1253/circj.CJ-19-0773
– volume: 160
  start-page: 2383
  year: 2021
  ident: B8
  article-title: Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.02.019
– volume: 50
  start-page: 4
  year: 2015
  ident: B15
  article-title: JSGE Clinical Practice Guidelines 2014: standards, methods, and process of developing the guidelines
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-014-1016-1
– volume: 52
  year: 2013
  ident: B18
  article-title: Association of Takayasu arteritis with HLA-B 67:01 and two amino acids in HLA-B protein
  publication-title: Rheumatol (Oxford)
  doi: 10.1093/rheumatology/ket241
– volume: 56
  start-page: 489
  year: 2021
  ident: B14
  article-title: Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-021-01784-1
– volume: 17
  year: 2014
  ident: B1
  article-title: Recent advances in Takayasu arteritis
  publication-title: Int J Rheum Dis
  doi: 10.1111/1756-185X.12309
– volume: 93
  start-page: 298
  year: 2013
  ident: B5
  article-title: Identification of multiple genetic susceptibility loci in Takayasu arteritis
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2013.05.026
– volume: 108
  start-page: 84
  year: 2021
  ident: B25
  article-title: Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study
  publication-title: Am J Hum Genet
  doi: 10.1016/j.ajhg.2020.11.014
SSID ssj0000493335
Score 2.3687077
Snippet It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. characterizes the co-occurrence, which is...
It has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the co-occurrence,...
BackgroundIt has been well documented that Takayasu arteritis (TAK) and ulcerative colitis (UC) coexist in the same patients. HLA-B*52 characterizes the...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 1387516
SubjectTerms Adult
Alleles
anti-integrin αvβ6 antibody
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Autoantibodies - blood
Autoantibodies - immunology
Colitis, Ulcerative - genetics
Colitis, Ulcerative - immunology
Female
Genotype
HLA-B52
HLA-B52 Antigen - genetics
HLA-B52 Antigen - immunology
Humans
Immunology
Integrins - immunology
Japan - epidemiology
Male
Middle Aged
Takayasu Arteritis - genetics
Takayasu Arteritis - immunology
Takayasu’s arteritis
ulcerative colitis
vasculitis
Young Adult
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LatwwFBUhUMgmNGkezgsVsgtOxnrY0jIpCaHQrhLITsh6EKeNHWbswHxW-iH5pl5JTpgphW66MsgGi3N9uefIV0cIHUMNA9nDRe5KQ3NmOMllyWQuofhZEzzP49LFt-_l9S37esfvFo76Cj1hyR44AXdm-MTWpKgNpCaz0mnvQDYIKHskbOOMah1q3oKYeki8l1LK0y4ZUGHyzDePjwPoQcJOCwokPRxwvlCJomH_31jmn82SC9Xn6iNaH2kjPk_T3UArrt1EH9JBkvNPSJ23fZMn64emxa8vz6-_SgygNXVn5xiGbvQPPdezAccezmBkhEdL1RkOa7G4m8ZrN_R4-GlcMgTHJrbHzbbQ7dXlzZfrfDw6ITeMTPpcaCMqWxRW1MaWTDDOiLGO1Zx6ZisniTcVFR7SkRReGg2szhGuvaaaA-mm22i17Vq3i3AtgJJxBkqQUVBTtaCilN6AquZeQDZn6OQNRvWUHDIUKIsAuoqgqwC6GkHP0EVA-v3J4G4dByDmaoy5-lfMM_T5LU4KsiH84tCt64aZAgE0oSLEP0M7KW7vr4IJCEarKkNiKaJLc1m-0zb30XE71JVAbPb-x-z30VpAJHZNygO02k8HdwjMpq-P4kf8G0Bu9r8
  priority: 102
  providerName: Directory of Open Access Journals
Title Anti-integrin αvβ6 antibody in Takayasu arteritis patients with or without ulcerative colitis
URI https://www.ncbi.nlm.nih.gov/pubmed/38784377
https://www.proquest.com/docview/3060380004
https://pubmed.ncbi.nlm.nih.gov/PMC11111853
https://doaj.org/article/c50db21bc1534d9eafe0268317222270
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LbtQwFLVKERIbxJtQqIzEDrlM_IqzQKhUlAqprDrS7CzHDwi0CUwS1Pks-JB-E9dOpuqgsmCTKE6UONe-uec49rkIvYQYBrRHKOKlZYRbQUkpeUlKCH7ORs3zNHRx_EkezfnHhVhsoXW6o8mA3bXULuaTmi9P985_rN6Cw7-JjBPi7etQn50NQPUo38sZ4O9c3kA3ITIV0VGPJ7j_dUTDjKWcm7mUnEBf5uM6mn_cZiNWJUn_63Do39Mpr8Snw7vozgQs8f7YE-6hLd_cR7fGVJOrB0jvN31NRnGIusEXv35e_JYYzFpXrVthKDox38zKdANOszyj1BGeRFc7HEdrcbtM-3bo8XBq_SgZjm2aQNc9RPPD9ycHR2RKrkAsp7OeKGNV4fLcqco6yRUXnFrneSVY4K7wJQ22YCqAw9I8lNYA7vNUmGCYEQDL2SO03bSNf4JwpQC0CQ5ckTPgW5ViSpbBAu8WQYG_Z-jV2oz6-6ihoYF7RKPrZHQdja4no2foXbT05ZVR_zoVtMvPenInbcXMVTSvLHywuSu9CR7IpAIwROPi3lmGXqzbSYO_xJ8gpvHt0GmgSDOmYl_I0OOx3S4fBRVQnBVFhtRGi27UZfNMU39Jmtwx8kTo8_S_3nUH3Y6HaQJl-Qxt98vBPweQ01e7aXAAth8W-W7qxX8At8D7dg
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-integrin+%CE%B1v%CE%B26+antibody+in+Takayasu+arteritis+patients+with+or+without+ulcerative+colitis&rft.jtitle=Frontiers+in+immunology&rft.au=Ishikawa%2C+Yuki&rft.au=Yoshida%2C+Hiroyuki&rft.au=Yoshifuji%2C+Hajime&rft.au=Ohmura%2C+Koichiro&rft.date=2024-05-09&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=15&rft_id=info:doi/10.3389%2Ffimmu.2024.1387516&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fimmu_2024_1387516
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon